|
[1] CUBERO FJ,NIETO N. Kupffer cells and alcoholic liver disease[J]. Rev Esp Enferm Dig,2006,98(6):460-472.
|
|
[2] ZIMMERMANN HW,SEIDLER S,NATTERMANN J,et al.Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis[J]. PLo S One,2010,5(6):e11049.
|
|
[3] TONG PY,TOLLEFSEN SE,KORNFELD S. The cation-independent mannose 6-phosphate receptor binds insulin-like growth factor II[J]. J Biol Chem,1988,263(6):2585-2588.
|
|
[4] TONG PY,GREGORY WKORNFELD S. Ligand interactions of the cation-independent mannose 6-phosphate receptor.The stoichiometry of mannose 6-phosphate binding[J]. J Biol Chem,1989,264(14):7962-7969.
|
|
[5] BELJAARS L,MOLEMA G,WEERT B,et al. Albumin modified with mannose 6-phosphate:A potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells[J]. Hepatology,1999,29(5):1486-1493.
|
|
[6] KLEIN S,van BEUGE MM,GRANZOW M,et al. HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects[J]. J Hepatol,2012,57(6):1220-1227.
|
|
[7] MORENO M,GONZALO T,KOK RJ,et al. Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats[J].Hepatology,2010,51(3):942-952.
|
|
[8] ADRIAN JE,POELSTRA K,SCHERPHOF GL,et al. Interaction of targeted liposomes with primary cultured hepatic stellate cells:Involvement of multiple receptor systems[J]. J Hepatol,2006,44(3):560-567.
|
|
[9] van BEUGE MM,PRAKASH J,LACOMBE M,et al. Enhanced effectivity of an ALK5-inhibitor after cell-specific delivery to hepatic stellate cells in mice with liver injury[J]. PLo S One,2013,8(2):e56442.
|
|
[10] YE Z,CHENG K,GUNTAKA RV,et al. Targeted delivery of a triplex-forming oligonucleotide to hepatic stellate cells[J].Biochemistry,2005,44(11):4466-4476.
|
|
[11] YANG N,SINGH SMAHATO RI. Targeted TFO delivery to hepatic stellate cells[J]. J Control Release,2011,155(2):326-330.
|
|
[12] ZHAO Z,LI Y,JAIN A,et al. Development of a peptidemodified siRNA nanocomplex for hepatic stellate cells[J].Nanomedicine,2018,14(1):51-61.
|
|
[13] CHEN Z,JIN W,LIU H,et al. Discovery of peptide ligands for hepatic stellate cells using phage display[J]. Mol Pharm,2015,12(6):2180-2188.
|
|
[14] CHEN Z,LIU H,JAIN A,et al. Discovery of aptamer ligands for hepatic stellate cells using SELEX[J]. Theranostics,2017,7(12):2982-2995.
|
|
[15] IKEDA K,WAKAHARA T,WANG YQ,et al. In vitro migratory potential of rat quiescent hepatic stellate cells and its augmentation by cell activation[J]. Hepatology,1999,29(6):1760-1767.
|
|
[16] KOCABAYOGLU P,LADE A,LEE YA,et al. beta-PDGF receptor expressed by hepatic stellate cells regulates fibrosis in murine liver injury,but not carcinogenesis[J]. J Hepatol,2015,63(1):141-147.
|
|
[17] CLEMENTS JM,BAWDEN LJ,BLOXIDGE RE,et al. Two PDGF-B chain residues,arginine 27 and isoleucine 30,mediate receptor binding and activation[J]. EMBO J,1991,10(13):4113-4120.
|
|
[18] BELJAARS L,WEERT B,GEERTS A,et al. The preferential homing of a platelet derived growth factor receptor-recognizing macromolecule to fibroblast-like cells in fibrotic tissue[J]. Biochem Pharmacol,2003,66(7):1307-1317.
|
|
[19] BANSAL R,PRAKASH J,de RUITER M,et al. Interferon gamma peptidomimetic targeted to hepatic stellate cells ameliorates acute and chronic liver fibrosis in vivo[J]. J Control Release,2014,179:18-24.
|
|
[20] BELCHER JM,SANYAL AJ,PEIXOTO AJ,et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury[J]. Hepatology,2014,60(2):622-632.
|
|
[21] KLEIN S,FROHN F,MAGDALENO F,et al. Rho-kinase inhibitor coupled to peptide-modified albumin carrier reduces portal pressure and increases renal perfusion in cirrhotic rats[J]. Sci Rep,2019,9(1):2256.
|
|
[22] WILHELM A,SHEPHERD EL,AMATUCCI A,et al. Interaction of TWEAK with Fn14 leads to the progression of fibrotic liver disease by directly modulating hepatic stellate cell proliferation[J]. J Pathol,2016,239(1):109-121.
|
|
[23] ZHANG F,ZHANG M,WANG A,et al. TWEAK increases SIRT1 expression and promotes p53 deacetylation affecting human hepatic stellate cell senescence[J]. Cell Biol Int,2017,41(2):147-154.
|
|
[24] HUANG L,XIE J,BI Q,et al. Highly selective targeting of hepatic stellate cells for liver fibrosis treatment using a denantiomeric peptide ligand of Fn14 identified by mirror-image mRNA display[J]. Mol Pharm,2017,14(5):1742-1753.
|
|
[25] WALD O,PAPPO O,SAFADI R,et al. Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus[J]. Eur J Immunol,2004,34(4):1164-1174.
|
|
[26] HONG F,TUYAMA A,LEE TF,et al. Hepatic stellate cells express functional CXCR4:role in stromal cell-derived factor-1alpha-mediated stellate cell activation[J]. Hepatology,2009,49(6):2055-2067.
|
|
[27] SAIMAN Y,AGARWAL R,HICKMAN DA,et al. CXCL12 induces hepatic stellate cell contraction through a calcium-independent pathway[J]. Am J Physiol Gastrointest Liver Physiol,2013,305(5):g375-g382.
|
|
[28] SAIMAN Y,JIAO J,FIEL MI,et al. Inhibition of the CXCL12/CXCR4 chemokine axis with AMD3100,a CXCR4 small molecule inhibitor,worsens murine hepatic injury[J]. Hepatol Res,2015,45(7):794-803.
|
|
[29] CHOW LN,SCHREINER P,NG BY,et al. Impact of a CXCL12/CXCR4 antagonist in bleomycin(BLM)induced pulmonary fibrosis and carbon tetrachloride(CCl4)induced hepatic fibrosis in mice[J]. PLo S One,2016,11(3):e0151765.
|
|
[30] KOLLET O,SHIVTIEL S,CHEN YQ,et al. HGF,SDF-1,and MMP-9 are involved in stress-induced human CD34+stem cell recruitment to the liver[J]. J Clin Invest,2003,112(2):160-169.
|
|
[31] XIAO LING K,PENG L,JIAN FENG Z,et al. Stromal derived factor-1/CXCR4 axis involved in bone marrow mesenchymal stem cells recruitment to injured liver[J]. Stem Cells Int,2016,2016:8906945.
|
|
[32] LIU CH,CHAN KM,CHIANG T,et al. Dual-functional nanoparticles targeting CXCR4 and delivering antiangiogenic siRNA ameliorate liver fibrosis[J]. Mol Pharm,2016,13(7):2253-2262.
|
|
[33] SUNG YC,LIU YC,CHAO PH,et al. Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development[J]. Theranostics,2018,8(4):894-905.
|
|
[34] ULLAH A,WANG K,WU P,et al. CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGFbeta-induced HSC-T6 cells activation[J].Int J Nanomedicine,2019,14:2927-2944.
|
|
[35] SENOO H,MEZAKI YFUJIWARA M. The stellate cell system(vitamin A-storing cell system)[J]. Anat Sci Int,2017,92(4):387-455.
|
|
[36] O'BYRNE SMBLANER WS. Retinol and retinylesters:Biochemistry and physiology[J]. J Lipid Res,2013,54(7):1731-1743.
|
|
[37] SATO Y,MURASE K,KATO J,et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone[J]. Nat Biotechnol,2008,26(4):431-442.
|
|
[38] PARK S,CHOI S,LEE MG,et al. Retinol binding protein-albumin domain III fusion protein deactivates hepatic stellate cells[J]. Mol Cells,2012,34(6):517-522.
|
|
[39] LEE H,JEONG H,PARK S,et al. Fusion protein of retinolbinding protein and albumin domain III reduces liver fibrosis[J]. EMBO Mol Med,2015,7(6):819-830.
|
|
[40] LI D,HE L,GUO H,et al. Targeting activated hepatic stellate cells(a HSCs)for liver fibrosis imaging[J]. EJNMMI Res,2015,5(1):71.
|
|
[41] BELJAARS L,MOLEMA G,SCHUPPAN D,et al. Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor[J]. J Biol Chem,2000,275(17):12743-12751.
|
|
[42] YANG J,HOU Y,JI G,et al. Targeted delivery of the RGDlabeled biodegradable polymersomes loaded with the hydrophilic drug oxymatrine on cultured hepatic stellate cells and liver fibrosis in rats[J]. Eur J Pharm Sci,2014,52:180-190.
|
|
[43] DU SL,PAN H,LU WY,et al. Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats[J]. J Pharmacol Exp Ther,2007,322(2):560-568.
|
|
[44] SAMUELSSON E,SHEN H,BLANCO E,et al. Contribution of Kupffer cells to liposome accumulation in the liver[J]. Colloids Surf B Biointerfaces,2017,158:356-362.
|
|
[45] ALLEN TMCHONN A. Large unilamellar liposomes with low uptake into the reticuloendothelial system[J]. FEBS Lett,1987,223(1):42-46.
|
|
[46] KLIBANOV AL,MARUYAMA K,TORCHILIN VP,et al. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes[J]. FEBS Lett,1990,268(1):235-237.
|
|
[47] GABIZON A,PAPAHADJOPOULOS D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors[J]. Proc Natl Acad Sci U S A,1988,85(18):6949-6953.
|
|
[48] ADRIAN JE,POELSTRA K,SCHERPHOF GL,et al. Effects of a new bioactive lipid-based drug carrier on cultured hepatic stellate cells and liver fibrosis in bile duct-ligated rats[J]. J Pharmacol Exp Ther,2007,321(2):536-543.
|
|
[49] EL-MEZAYEN NS,EL-HADIDY WF,EL-REFAIE WM,et al. Hepatic stellate cell-targeted imatinib nanomedicine versus conventional imatinib:A novel strategy with potent efficacy in experimental liver fibrosis[J]. J Control Release,2017,266:226-237.
|
|
[50] ZHANG SL,MA L,ZHAO J,et al. The phenylethanol glycoside liposome inhibits PDGF-induced HSC activation via regulation of the FAK/PI3K/Akt signaling pathway[J]. Molecules,2019,24(18). pii:E3282.
|
|
[51] PENG F,TEE JK,SETYAWATI MI,et al. Inorganic nanomaterials as highly efficient inhibitors of cellular hepatic fibrosis[J].ACS Appl Mater Interfaces,2018,10(38):31938-31946.
|
|
[52] TEE JK,ONG CN,BAY BH,et al. Oxidative stress by inorganic nanoparticles[J]. Wiley Interdiscip Rev Nanomed Nanobiotechnol,2016,8(3):414-438.
|
|
[53] YU Y,DUAN J,LI Y,et al. Silica nanoparticles induce liver fibrosis via TGF-beta1/Smad3 pathway in ICR mice[J]. Int J Nanomedicine,2017,12:6045-6057.
|
|
[54] RAMADI KB,MOHAMED YA,AL-SBIEI A,et al. Acute systemic exposure to silver-based nanoparticles induces hepatotoxicity and NLRP3-dependent inflammation[J]. Nanotoxicology,2016,10(8):1061-1074.
|
|
[55] TORCHILIN VP. Micellar nanocarriers:pharmaceutical perspectives[J]. Pharm Res,2007,24(1):1-16.
|
|
[56] KWON GS. Polymeric micelles for delivery of poorly watersoluble compounds[J]. Crit Rev Ther Drug Carrier Syst,2003,20(5):357-403.
|
|
[57] WU J,HUANG J,KUANG S,et al. Synergistic microRNA therapy in liver fibrotic rat using MRI-visible nanocarrier targeting hepatic stellate cells[J]. Adv Sci(Weinh),2019,6(5):1801809.
|
|
[58] MOVASSAGHIAN S,MERKEL OMTORCHILIN VP. Applications of polymer micelles for imaging and drug delivery[J]. Wiley Interdiscip Rev Nanomed Nanobiotechnol,2015,7(5):691-707.
|
|
[59] JIANG Z,GUAN J,QIAN J,et al. Peptide ligand-mediated targeted drug delivery of nanomedicines[J]. Biomater Sci,2019,7(2):461-471.
|
DownLoad: